Auspex Pharmaceuticals

Teva completes acquisition of Auspex Pharmaceuticals

Wednesday, May 6, 2015

Teva Pharmaceutical Industries has completed the acquisition of Auspex Pharmaceuticals through the successful tender offer for all of the outstanding shares of common stock of Auspex at $101 per share in cash, representing total consideration of approximately $3.2 billion in enterprise value and approximately $3.5 billion in equity value. The acquisition is expected to enhance Teva’s revenue and earnings growth profile and strengthen its core central nervous system franchise. Auspex now is a wholly owned subsidiary of Teva.

[Read More]

Auspex Pharmaceuticals appoints Lynn Bleil, Scott Greer to board of directors

Friday, May 9, 2014

Auspex Pharmaceuticals, a late clinical stage biopharmaceutical company focused on developing and commercializing novel medicines for the treatment of orphan diseases, has announced the expansion of its board of directors with the appointment of two new members: Lynn D. Bleil, former leader of McKinsey & Company’s West Coast Healthcare Practice and a leader of the worldwide Healthcare Practice; and R. Scott Greer, managing director of Numenor Ventures, and former founder, chairman and CEO of Abgenix. The total number of Auspex board members is increased to nine.

[Read More]